CASE REPORTS

Difficult diagnosis of the fragile X syndrome made possible by direct detection of DNA mutations

Jack Tarleton, Silas Wong, Dominique Heitz, Charles Schwartz

Abstract
Genetic recombination near the fragile X locus (Xq27.3) has frequently been a problem in linkage studies of families in which the fragile X is segregating. This case report illustrates the resolution of a difficult situation in a fragile X family for whom cytogenetic studies were inconclusive and where recombination had twice confounded attempts at prenatal DNA diagnosis by RFLP analysis. Using a newly developed DNA probe, StB12.3, for direct detection of DNA instability in the fragile X locus, the presence of the fragile X was ascertained definitively in a prenatal DNA sample.

(J Med Genet 1992;29:726-9)

The fragile X syndrome may be the most common cause of inherited mental retardation with an incidence of approximately 1 in 5000 males and 1 in 2500 females.1 The mode of inheritance does not fit neatly into a mendelian pattern but may be considered to be X linked dominant with reduced penetrance in females. Carrier females may or may not be mentally retarded and may or may not show the fragile site cytogenetically. Transmission of the fragile X to offspring can occur through carrier females as well as normal carrier males, termed normal transmitting males, who can be shown to be obligate carriers of a fragile X chromosome but do not manifest any of the symptoms of the syndrome nor do they exhibit the fragile site cytogenetically.

Highly consistent and reproducible detection by cytogenetic studies of the fragile site in female carriers is difficult. The fragile X site can only be induced after cell culturing under conditions where the deoxypyrimidine pool is perturbed2 and frequent false negative results occur. Failures to detect the fragile site cytogenetically in some patients, or detecting a small number of X chromosomes having questionable constrictions in Xq27.3, have led to many instances where attempts to diagnose the fragile X syndrome have been inconclusive.

During the 1980s it became possible to use restriction fragment length polymorphisms (RFLPs) flanking the fragile X locus to follow the segregation of the fragile X syndrome through a family with affected members. Occasionally, genetic recombination is a confounding problem when using RFLPs in linkage analysis. In some situations it is impossible to determine whether a recombination event has included the fragile X locus, leading to tremendous anxiety in the families being studied. We report here an example of the resolution of difficult fragile X diagnostic situation using direct detection of mutations within the fragile X gene.

Case report
Our laboratory was contacted in December 1990, to perform prenatal DNA studies on amniocytes using RFLP analysis for a family where the uncle of the fetus had been diagnosed as having the fragile X syndrome. Fig 1 illustrates the family structure and the results of the linkage analysis. We had earlier performed a prenatal study in 1988 for a previous pregnancy in this family with the result that an unaffected male had been born (III.2). In the DNA study for the first pregnancy, the linkage analysis had shown that the mother (II.4) inherited a recombinant X chromosome from her mother (I.2). With the DNA markers in use in 1988 it was not possible to determine whether the recombination in patient II.4 had included the fragile X locus. Repeated cytogenetic studies of patient II.4 had all been negative for the presence of fragile X chromosomes. Thus, her carrier status had not been resolved when we were contacted about the second study. Using the DNA marker VK21 (DXS296), which was not available in 1988, we were able to estimate that she had approximately a 90% risk of being a fragile X carrier based on the possibility of recombination occurring somewhere between the proximal marker cX35.7 and distally located VK21. Furthermore, the oldest child (III.1) of this woman had inherited her recombinant X chromosome and as a result had a high risk of being a fragile X carrier.

The fetus (III.3) in the present study was determined to be female by chromosome analysis and to have a single questionable cell, out of 300 studied, containing an X chromosome with a very slight constriction in the fragile X region. Linkage analysis showed that
Difficult diagnosis of the fragile X syndrome made possible by direct detection of DNA mutations

Southern blot analysis using a DNA probe (StB12.3)\(^7\) located just distal to the CCG repeat segment, along with methylation sensitive (EagI) and methylation insensitive (EcoRI) restriction enzyme digestion, can differentiate affected from normal males as well as normal transmitting males from normal males.\(^4\) In addition, carrier females can be differentiated from normal females.\(^4\) Restriction digestion with EcoRI will generate a 5-2 kb band from FMR-1 containing the mutable region. This DNA fragment may be further digested by EagI into a 2-8 kb band, containing the mutable region, and a 2-4 kb band. Both the 5-2 kb and 2-8 kb bands can be detected by StB12.3. The EagI site is located in a CpG island within or near to 250 bp upstream of the mutable region. Normal males and females will have a 2-8 kb band on Southern blot analysis if the EagI site is unmethylated, as is normally the case. Normal females also will have a 5-2 kb band generated from the inactive X chromosome where the EagI site is blocked by normal methylation.

Using the direct detection approach we have been able to resolve the situation in our family which only recently seemed intractable. Fig 2 shows an autoradiograph produced from Southern blot analysis of the family. The various family members can definitely be categorised as to their particular fragile X status by this method.\(^4\) Lane I contains DNA from the uncle of the fetus (II.2) and exhibits a normal male pattern of a single band at 2-8 kb. Patient II.3 (lane 2), the fragile X affected uncle of the fetus, has a smeared band of approximately 6 to 8 kb indicative of instability of the fragile X region. Amplification of the unstable region by an as yet unknown mechanism may explain the large expansion of the fragile X mutation. Lanes 3 to 5 contain DNA from the grandmother of the fetus (I.2), the mother of the fetus (II.4), and the sister of the fetus (III.1), respectively. The four band pattern seen best in lane 5 is typical of that found in fragile X non-expressing carrier females who have no manifestation of the fragile X phenotype or cytogenetic expression of the fragile site. All three have patterns indicative of non-expressing female carriers though it appears that with each succeeding generation some DNA amplification occurs at the fragile X locus in these females. Lane 6 contains DNA from the father of the fetus (II.5). Lane 7 contains DNA from the aunt of the fetus (II.1) and has two bands at 2-8 kb and 5-2 kb typical of a normal female. Lane 8 contains DNA from the normal brother (III.2) of the fetus. Fetal DNA is contained in lane 9. Over-exposure of the autoradiograph was necessary to show a faint 5-2 kb band with the result that the background signal is increased.

**Discussion**

In the fetal DNA sample (fig 2, lane 9), the pattern of a smeared band at the 6 to 8 kb region plus a dark 2-8 kb band and faint 5-2 kb band may indicate two events: (1) amplification of DNA in the fragile X chromosomes.
fragments the performed overnight four approximately mechanism of DNA fragments occurs present, not FMR-1 near if X mutable gile approximately A ple studied here 8 kb normal allele. CCXG X mutable gile which X mutable gile is X mutable gile much more or less random.7 The Southern blot pattern of carrier females who do not have expression of the fragile X syndrome is very frequently distinct from those carrier females who do have expression of the fragile X syndrome.4 It appears that the four distinct band pattern typically seen in non-expressing carrier females correlates, to a high degree, with normal intelligence, no cytogenetic expression, and little or no expression of the dysmorphic features associated with the fragile X syndrome. In contrast, the pattern seen in the fetus studied here appears to be highly correlated with cytogenetic expression but less correlated with mental retardation. An initial estimate is that about 53% of fragile X females having a pattern similar to that seen in the fetal DNA studied here are mentally retarded.4 Our laboratory has also found a comparable percentage of affected females with this pattern. Thus, the Southern blot patterns of carrier females have less predictive value of the potential of a female to be affected with the dysmorphic features of the fragile X syndrome.

At nearly the same time that direct fragile X testing became possible, the baby was delivered. Cytogenetic testing performed on cells isolated from cord blood showed the presence of a low level of cytogenetic expression of the fragile site (3 to 4%). Currently, at 5 months of age, the baby has no overt signs of developmental delay but one might not expect to see any manifestation at this early time in her development. Thus, clarification of the possible correlation between the extent of DNA alteration as detected by direct DNA analysis and mental retardation in this child awaits the passage of time. The accumulation of more experience through testing of large numbers of females with a pattern similar to the fetus studied here should allow a better understanding of the relationship between the molecular alterations and mental retardation.

In summary, using a newly developed probe near the fragile X mutation, we have been able
Difficult diagnosis of the fragile X syndrome made possible by direct detection of DNA mutations

We thank Dr J-L Mandel for the use of DNA probes StB12.3 and St14 and critical reading of this manuscript; F Rousseau for communicating the Southern blot protocol used in this study; and Ms J A Babb for technical assistance. cX55.7 was a gift from Dr P L Pearson. 4D8 was isolated in the laboratory of Dr R L Nussbaum and given to us by Dr K Davies. VK21 was a gift from Dr G Suthers. We dedicate the manuscript to the memory of Dr Isabelle Oberle who worked to develop the testing protocol in Dr Mandel’s laboratory.